Phathom Pharmaceuticals Inc 's ability to collect accounts receivable sequentially worsen to 3.08, indicating more challenging environment then in the fourth quarter 2025, but still, it is a far cry from any concerns. Phathom Pharmaceuticals Inc 's Accounts Receivable average collection period in the Mar 31 2026 quarter, has increased to 119 days, from 116 days, in the Dec 31 2025 quarter.

If we take a look into Healthcare sector 476 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 2508 to 3104.

What is Receivable Turnover Ratio?
What is Phathom Pharmaceuticals Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PHAT Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Receivable Change	121.99 %	101.38 %	165.01 %	371.22 %	837.46 %
Y / Y Revenue Change	104.43 %	94.12 %	202.74 %	439.36 %	1391.58 %
Receivable Turnover Ratio (TTM)	3.08	3.16	3.23	3.09	3.06
PHAT's Total Ranking	# 3104	# 2508	# 1891	# 1917	# 2944
Accounts Receivable average collection period days	118	115	113	118	119
Seq. Receivable Change	3.32 %	40.04 %	8.85 %	40.95 %	-6.27 %
Seq. Revenue Change	1.25 %	16.32 %	25.32 %	38.51 %	-3.86 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 153
Healthcare Sector	# 477
Overall Market	# 3104

Receivable Turnover Ratio Statistics
High	Average	Low
3.23	3.06	2.81
(Sep 30 2025)		(Sep 30 2024)

PHAT Company Profile • Back to PHAT Efficiency Comparisons • Compare PHAT Receivables Turnover Ratio to its Competitors

Financial Statements
Phathom Pharmaceuticals Inc 's Accounts Receivable	$ 81 Millions	Visit PHAT's Balance sheet
Phathom Pharmaceuticals Inc 's Sales TTM	$ 205 Millions	Visit PHAT's Income Statement
Sources of PHAT's Revenues		Visit PHAT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
PHAT's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
PHAT's Growth Rates	PHAT's Roa	PHAT's Inventory Turnover Ratio	PHAT's Dividend Comparisons
PHAT's Profitability Ratios	PHAT's Roi	PHAT's Asset Turnover Ratio	PHAT's Dividend Growth
PHAT's Valuation Ratios	PHAT's Roe	PHAT's Financial Strength Ratios	PHAT's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2026	Receivable at quarter ending Mar 31 2026
Biogen Inc	6.96	$ 9,937.400 Millions	$ 1,427.475 Millions
Tarsus Pharmaceuticals Inc	6.96	$ 589.621 Millions	$ 84.723 Millions
Beyond Air Inc	6.95	$ 6.065 Millions	$ 0.873 Millions
Universal Health Services Inc	6.94	$ 17,760.291 Millions	$ 2,558.777 Millions
Insulet Corporation	6.93	$ 2,900.800 Millions	$ 418.625 Millions
Medpace Holdings Inc	6.92	$ 2,678.268 Millions	$ 386.904 Millions
Clearpoint Neuro Inc	6.92	$ 40.614 Millions	$ 5.868 Millions
Merit Medical Systems Inc	6.90	$ 1,542.047 Millions	$ 223.614 Millions
Solventum Corporation	6.89	$ 8,262.000 Millions	$ 1,198.750 Millions
Edwards Lifesciences Corporation	6.85	$ 6,303.300 Millions	$ 920.125 Millions
Fate Therapeutics Inc	6.83	$ 6.316 Millions	$ 0.924 Millions
Neuropace Inc	6.83	$ 98.926 Millions	$ 14.490 Millions
Ceribell Inc	6.83	$ 94.389 Millions	$ 13.828 Millions
Arcturus Therapeutics Holdings Inc	6.83	$ 54.710 Millions	$ 8.016 Millions
Schrodinger Inc	6.81	$ 254.905 Millions	$ 37.438 Millions
Genedx Holdings Corp	6.81	$ 442.908 Millions	$ 65.066 Millions
Catheter Precision Inc	6.78	$ 1.108 Millions	$ 0.164 Millions
Carlisle Companies Incorporated	6.77	$ 4,976.200 Millions	$ 735.475 Millions
3m Company	6.75	$ 25,024.000 Millions	$ 3,706.000 Millions
Seastar Medical Holding Corp	6.73	$ 1.436 Millions	$ 0.214 Millions
Insmed Inc	6.71	$ 737.256 Millions	$ 109.926 Millions
Nuo Therapeutics Inc	6.70	$ 4.036 Millions	$ 0.602 Millions
Myriad Genetics Inc	6.70	$ 828.000 Millions	$ 123.525 Millions
Phibro Animal Health Corporation	6.70	$ 1,500.123 Millions	$ 223.852 Millions
Ufp Technologies Inc	6.68	$ 608.621 Millions	$ 91.103 Millions
Pulmonx Corporation	6.68	$ 87.841 Millions	$ 13.151 Millions
Beone Medicines Ltd	6.68	$ 5,737.861 Millions	$ 859.289 Millions
Blue Water Vaccines Inc	6.68	$ 0.735 Millions	$ 0.110 Millions
Avanos Medical Inc	6.67	$ 714.200 Millions	$ 107.125 Millions
Stryker Corp	6.66	$ 25,270.000 Millions	$ 3,792.750 Millions

Date modified: 2026-08-30T15:00:01+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.